AtriCure Inc. advanced to a 52-week high of $50.00 on Wednesday after reporting adjusted earnings that exceeded Wall Street expectations for the second quarter of 2026.
The medical device manufacturer posted adjusted earnings of $0.18 per share, compared with a projected loss of $0.01 per share, while revenue reached $153.6 million, topping the $151.84 million estimate. Year-to-date, the stock has gained nearly 24%, and over the past six months, it has surged 58%. Over the last 12 months, the shares have risen 40.7%.
Analysts responded with upward revisions to price targets. Needham raised its target to $64.00 and maintained a buy rating, citing optimism surrounding the BoxX-NoAF randomized clinical study. Piper Sandler lifted its target to $60.00, pointing to a new quality measure from the Society of Thoracic Surgeons that could support AtriCure's open ablation business. BTIG also raised its target to $55.00, highlighting the potential impact of the new metric on Open Ablation products.
InvestingPro described AtriCure's stock as overvalued relative to its fair value estimate and noted that the Relative Strength Index indicated overbought conditions. The shares closed at $49.85 on Tuesday, just below the intraday peak.
AtriCure develops and markets devices for the treatment of atrial fibrillation and related cardiac conditions.
